S'abonner

Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations - 06/06/18

Doi : 10.1016/j.jaci.2018.02.040 
Patrick M. Brunner, MD a, Ariel Israel, MD, PhD b, Ning Zhang, MD c, Alexandra Leonard, BA c, Huei-Chi Wen, MD, PhD c, Thy Huynh, MD d, Gary Tran, MD d, Sarah Lyon, MD d, Giselle Rodriguez, MD d, Supriya Immaneni, BS d, Annette Wagner, MD d, Xiuzhong Zheng, MSc a, Yeriel D. Estrada, BS c, Hui Xu, MSc c, James G. Krueger, MD, PhD a, Amy S. Paller, MD d, , Emma Guttman-Yassky, MD, PhD a, c,
a Laboratory for Investigative Dermatology, Rockefeller University, New York, NY 
b Department of Family Medicine, Clalit Health Services, Jerusalem, Israel 
c Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 
d Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Ill 

Corresponding author: Emma Guttman-Yassky, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai Medical Center, 5 E 98th St, New York, NY 10029.Department of DermatologyIcahn School of Medicine at Mount Sinai Medical Center5 E 98th StNew YorkNY10029

Abstract

Background

Although atopic dermatitis (AD) often starts in early childhood, detailed tissue profiling of early-onset AD in children is lacking, hindering therapeutic development for this patient population with a particularly high unmet need for better treatments.

Objective

We sought to globally profile the skin of infants with AD compared with that of adults with AD and healthy control subjects.

Methods

We performed microarray, RT-PCR, and fluorescence microscopy studies in infants and young children (<5 years old) with early-onset AD (<6 months disease duration) compared with age-matched control subjects and adults with longstanding AD.

Results

Transcriptomic analyses revealed profound differences between pediatric patients with early-onset versus adult patients with longstanding AD in not only lesional but also nonlesional tissues. Although both patient populations harbored TH2-centered inflammation, pediatric AD also showed significant TH17/TH22 skewing but lacked the TH1 upregulation that characterizes adult AD. Pediatric AD exhibited relatively normal expression of epidermal differentiation and cornification products, which is downregulated in adults with AD. Defects in the lipid barrier (eg, ELOVL fatty acid elongase 3 [ELOVL3] and diacylglycerol o-acyltransferase 2 [DGAT2]) and tight junction regulation (eg, claudins 8 and 23) were evident in both groups. However, some lipid-associated mediators (eg, fatty acyl-CoA reductase 2 and fatty acid 2-hydroxylase) showed preferential downregulation in pediatric AD, and lipid barrier genes (FA2H and DGAT2) showed inverse correlations with transepidermal water loss, a functional measure of the epidermal barrier.

Conclusions

Skin samples from children and adult patients with AD share lipid metabolism and tight junction alterations, but epidermal differentiation complex defects are only present in adult AD, potentially resulting from chronic immune aberration that is not yet present in early-onset disease.

Le texte complet de cet article est disponible en PDF.

Key words : Atopic dermatitis, pediatric, infant, skin barrier, skin inflammation

Abbreviations used : AD, CLDN, DEG, EDC, ELOVL, EREG, FLG, KYNU, LCE, STAT, TEWL


Plan


 Supported by a research grant from the LEO Foundation. P.M.B. was supported in part by grant no. UL1 TR0001866 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program.
 Disclosure of potential conflict of interest: P. M. Brunner received payment for lectures from Sanofi, Pfizer, and LEO Pharma. J. G. Krueger's institution and he personally received fees from Novartis, Pfizer, Amgen, Boehringer, Janssen, AbbVie, Leo Pharma, Acros; he personally received personal from Lilly, Biogen Idec, Escalier, Roche, Valeant, Allergan, Aurigene, and Asana; and his institution received personal fees from Innovaderm, BMS, Paraxel, Vitae, Kineta, Regeneron, Novan, BiogenMA, Sienna, UCB, and Allergan. A. S. Paller received consultancy fees from Dermira, Eli Lily, Expanscience, Galderma Laboratories, Menlo Therapeutics, Novartis Pharmaceuticals, Pfizer, Pierre Fabre Dermatologie, Regeneron/Sanofi, and Valeant Pharmaceuticals, and her institution received grants from Anacor, Astellas, and the Leo Foundation for other works. E. Guttman-Yassky personally received board membership from Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, Medimmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences and consultancy fees from Regeneron, Sanofi Aventis, Medimmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences, and her institution received grants for other works from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, Novartis, and UCB. The rest of the authors declare that they have no relevant conflicts of interest.


© 2018  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 141 - N° 6

P. 2094-2106 - juin 2018 Retour au numéro
Article précédent Article précédent
  • Ankyrin repeat domain 1 regulates innate immune responses against herpes simplex virus 1: A potential role in eczema herpeticum
  • Lianghua Bin, Xiaozhao Li, Brittany Richers, Joanne E. Streib, Jack W. Hu, Patricia Taylor, Donald Y.M. Leung
| Article suivant Article suivant
  • Single-cell profiling of peanut-responsive T cells in patients with peanut allergy reveals heterogeneous effector TH2 subsets
  • David Chiang, Xintong Chen, Stacie M. Jones, Robert A. Wood, Scott H. Sicherer, A. Wesley Burks, Donald Y.M. Leung, Charuta Agashe, Alexander Grishin, Peter Dawson, Wendy F. Davidson, Leah Newman, Robert Sebra, Miriam Merad, Hugh A. Sampson, Bojan Losic, M. Cecilia Berin

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.